Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review

doi:10.4251/wjgo.v13.i11.1813

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7435)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

473

WORD

124

HTML

5754

Figures (1-4)

202

Tables (1-3)

215

Sum=6768

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

296

Download

371

Sum=667

Nov 15, 2021 (publication date) through Jul 2, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1813-1832
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1813

Full Size Figure Download Figure

Figure 3 Preferred reporting items for systematic reviews and meta-analyses diagram.

Citation: Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1813-1832
URL: https://www.wjgnet.com/1948-5204/full/v13/i11/1813.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1813